- Bristol Myers Squibb (BMY, Financial) to present data from over 80 studies at ASCO 2025, showing results for more than 20 cancer types.
- Highlighted studies include Opdivo's long-term survival data and new results for earlier intervention in various cancers.
- New data on Reblozyl, BMS-986504, and Breyanzi, showcasing breakthrough treatments in oncology.
Bristol Myers Squibb (BMY) has announced it will unveil comprehensive data from its oncology portfolio and research pipeline during the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting. This presentation, set for May 30-June 3 in Chicago, Illinois, encompasses more than 80 company-sponsored and investigator-sponsored studies across over 20 cancer types, highlighting the company's extensive research platform.
A major focus will be on Opdivo® (nivolumab), with updates from several significant studies. Key highlights include the Phase 3 CheckMate -816 study demonstrating the 5-year overall survival (OS) for Opdivo combined with chemotherapy in resectable non-small cell lung cancer (NSCLC) and the Phase 3 CheckMate -577 study showcasing 5-year OS data for adjuvant Opdivo in esophageal cancer.
Additionally, the company will present new findings from the COMMANDS study, revealing the overall survival (OS) and duration of response (DoR) with Reblozyl® (luspatercept-aamt) for transfusion independence in certain myelodysplastic syndromes (MDS).
The presentations also include advancements in the oncology pipeline, such as the first-in-human Phase 1/2 study results for BMS-986504, identified as a potential first-in-class MTA-cooperative PRMT5 inhibitor for advanced solid tumors. Further insights are expected on Breyanzi® (lisocabtagene maraleucel), with data analysis from over 1,500 patients detailing management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in B-cell non-Hodgkin lymphoma treatment.
Dr. Samit Hirawat, Executive Vice President, Chief Medical Officer, and Head of Development at Bristol Myers Squibb, emphasized the company's commitment to leveraging deep expertise and innovative technologies to redefine the landscape of cancer care, aiming for enhanced patient outcomes.
